全文获取类型
收费全文 | 214877篇 |
免费 | 38057篇 |
国内免费 | 7224篇 |
专业分类
耳鼻咽喉 | 3554篇 |
儿科学 | 4587篇 |
妇产科学 | 4938篇 |
基础医学 | 17146篇 |
口腔科学 | 7125篇 |
临床医学 | 41297篇 |
内科学 | 43031篇 |
皮肤病学 | 4431篇 |
神经病学 | 19355篇 |
特种医学 | 7329篇 |
外国民族医学 | 42篇 |
外科学 | 30132篇 |
综合类 | 14969篇 |
现状与发展 | 63篇 |
一般理论 | 42篇 |
预防医学 | 20908篇 |
眼科学 | 5197篇 |
药学 | 12590篇 |
56篇 | |
中国医学 | 4859篇 |
肿瘤学 | 18507篇 |
出版年
2024年 | 1031篇 |
2023年 | 6540篇 |
2022年 | 5223篇 |
2021年 | 8259篇 |
2020年 | 9113篇 |
2019年 | 5749篇 |
2018年 | 10820篇 |
2017年 | 10552篇 |
2016年 | 11087篇 |
2015年 | 12757篇 |
2014年 | 16471篇 |
2013年 | 17782篇 |
2012年 | 12409篇 |
2011年 | 12912篇 |
2010年 | 12214篇 |
2009年 | 13315篇 |
2008年 | 9586篇 |
2007年 | 8718篇 |
2006年 | 9674篇 |
2005年 | 8518篇 |
2004年 | 5995篇 |
2003年 | 5136篇 |
2002年 | 4568篇 |
2001年 | 4318篇 |
2000年 | 3804篇 |
1999年 | 4422篇 |
1998年 | 3731篇 |
1997年 | 3451篇 |
1996年 | 3291篇 |
1995年 | 2881篇 |
1994年 | 2097篇 |
1993年 | 1569篇 |
1992年 | 1755篇 |
1991年 | 1445篇 |
1990年 | 1197篇 |
1989年 | 1124篇 |
1988年 | 1099篇 |
1987年 | 920篇 |
1986年 | 776篇 |
1985年 | 627篇 |
1984年 | 466篇 |
1983年 | 468篇 |
1982年 | 328篇 |
1981年 | 309篇 |
1980年 | 215篇 |
1979年 | 184篇 |
1978年 | 180篇 |
1977年 | 179篇 |
1976年 | 132篇 |
1974年 | 121篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
11.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
12.
13.
14.
15.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文
16.
17.
18.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
19.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
20.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献